MedInCell Stock Surpasses its 200-Day Moving Average, Up 84% Over the Year
MedInCell shows a sharp acceleration this Friday morning, trading at €23.74, up 3.31% from yesterday's close. The Montpellier-based biotech, specializing in extended-release drug technologies, is now trading above its 200-day moving average, in a generally stable Parisian market context.
In today's session, MedInCell shares are trading at €23.74, surpassing the upper Bollinger Band limit set at €23.48. This breakout represents a potential overbought signal, with the price at 107% of the band width. However, the RSI indicator, at 53, remains in the neutral zone, which does not yet confirm a sustained buying pressure excess. Regarding moving averages, the stock has moved above its MM200 (€23.60) after several weeks of hesitation, and remains comfortably above its MM50 (€22.87). This bullish crossover with the long-term average is a focal point for traders, especially as the next technical resistance threshold is identified at €24.94. In case of a pullback, the major support is at €20.24.
One-Year Stock Performance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Over the past year, MedInCell's stock performance has been spectacular with an increase of 84.46%, although the stock has lost 6.83% over the last three months before this rebound. The performance over the past seven days is +2.77%, indicating a recent resurgence of interest in the stock. The upcoming financial calendar could act as a catalyst. The company is set to publish its annual results for the fiscal year 2025-2026 on June 16, followed by the general meeting scheduled for September 10. These events will be closely watched as the very low beta of the stock (0.02) indicates a significant historical decorrelation with the market as a whole. During the session, the CAC 40 is up 0.26% at 8,267 points, while the SBF 120 is up 0.23%. In the healthcare sector, Sanofi is up 0.41% and UCB by 0.96%, in a moderately positive sector movement.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
